Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a single center phase 1 trail to observe safety and efficacy of metronomic
Capecitabine plus Camrelizumab as second-line regimen to treat head and neck cancer or
esophageal squamous cancer patients.
This study is one of the cohorts of a multi-cohort trial called Combination of Metronomic
Capecitabine with Camrelizumab for treatment of refractory solid tumor (McCrest) trial.